TG, I see your calc's and was just wondering this thought. What if they're are several deaths in the Leronlimab arm that are NOT related to the drug, doesn't that bode well for the CD-12 trial? We had some of those instances in the EIND trials, right? That in itself will improve the trial outcome IMO but if I'm wrong, please correct me since we don't know that until the trial is unblinded - GLTU

HCIT